Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Not in Nasdaq Compliance Following Resignation

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker is not in compliance with a Nasdaq regulation following the resignation of Collin D'Silva, an independent director and member of the firm's audit committee.

Bruker said in a filing with the US Securities and Exchange Commission on Friday that D'Silva had resigned his position on the audit committee as of March 9. As a result, the firm currently has only two members of its audit committee and is no longer in compliance with a Nasdaq rule that requires a company's audit committee to have a minimum of three members.

Bruker said that has until Sep. 7 to regain compliance with the Nasdaq rule, and added that it intends to fill the vacancy "as expeditiously as possible" prior to Sep. 7.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.